Abstract
Summary
A migraine is a primary headache disorder characterized by recurrent headaches that are moderate to severe. Typically, the headaches affect one half of the head, are pulsating in nature, and last from two to 72 hours. Associated symptoms may include nausea, vomiting, and sensitivity to light, sound, or smell. The pain is generally made worse by physical activity.
LPI (LP Information)' newest research report, the “Migraine Industry Forecast” looks at past sales and reviews total world Migraine sales in 2022, providing a comprehensive analysis by region and market sector of projected Migraine sales for 2023 through 2029. With Migraine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Migraine industry.
This Insight Report provides a comprehensive analysis of the global Migraine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Migraine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Migraine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Migraine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Migraine.
The global Migraine market size is projected to grow from US$ 5037.6 million in 2022 to US$ 8921 million in 2029; it is expected to grow at a CAGR of 8.5% from 2023 to 2029.
Globally, approximately 15% of people are affected by migraines. It most often starts at puberty and is worst during middle age. As of 2016 migraines is one of the most common causes of disability.
This report presents a comprehensive overview, market shares, and growth opportunities of Migraine market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Oral
Injectable
Nasal Sprays
Others
Segmentation by application
Hospitals
Clinics
Home Care
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
GlaxoSmithKline
Allergan
Amgen
Eli Lilly
Teva Pharma
Biohaven Pharma
Abbott Laboratories
Johnson & Johnson
Valeant Pharma
LPI (LP Information)' newest research report, the “Migraine Industry Forecast” looks at past sales and reviews total world Migraine sales in 2022, providing a comprehensive analysis by region and market sector of projected Migraine sales for 2023 through 2029. With Migraine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Migraine industry.
This Insight Report provides a comprehensive analysis of the global Migraine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Migraine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Migraine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Migraine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Migraine.
The global Migraine market size is projected to grow from US$ 5037.6 million in 2022 to US$ 8921 million in 2029; it is expected to grow at a CAGR of 8.5% from 2023 to 2029.
Globally, approximately 15% of people are affected by migraines. It most often starts at puberty and is worst during middle age. As of 2016 migraines is one of the most common causes of disability.
This report presents a comprehensive overview, market shares, and growth opportunities of Migraine market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Oral
Injectable
Nasal Sprays
Others
Segmentation by application
Hospitals
Clinics
Home Care
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
GlaxoSmithKline
Allergan
Amgen
Eli Lilly
Teva Pharma
Biohaven Pharma
Abbott Laboratories
Johnson & Johnson
Valeant Pharma
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Migraine Market Size 2018-2029
2.1.2 Migraine Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Migraine Segment by Type
2.2.1 Oral
2.2.2 Injectable
2.2.3 Nasal Sprays
2.2.4 Others
2.3 Migraine Market Size by Type
2.3.1 Migraine Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Migraine Market Size Market Share by Type (2018-2023)
2.4 Migraine Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Home Care
2.5 Migraine Market Size by Application
2.5.1 Migraine Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Migraine Market Size Market Share by Application (2018-2023)
3 Migraine Market Size by Player
3.1 Migraine Market Size Market Share by Players
3.1.1 Global Migraine Revenue by Players (2018-2023)
3.1.2 Global Migraine Revenue Market Share by Players (2018-2023)
3.2 Global Migraine Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Migraine by Regions
4.1 Migraine Market Size by Regions (2018-2023)
4.2 Americas Migraine Market Size Growth (2018-2023)
4.3 APAC Migraine Market Size Growth (2018-2023)
4.4 Europe Migraine Market Size Growth (2018-2023)
4.5 Middle East & Africa Migraine Market Size Growth (2018-2023)
5 Americas
5.1 Americas Migraine Market Size by Country (2018-2023)
5.2 Americas Migraine Market Size by Type (2018-2023)
5.3 Americas Migraine Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Migraine Market Size by Region (2018-2023)
6.2 APAC Migraine Market Size by Type (2018-2023)
6.3 APAC Migraine Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Migraine by Country (2018-2023)
7.2 Europe Migraine Market Size by Type (2018-2023)
7.3 Europe Migraine Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Migraine by Region (2018-2023)
8.2 Middle East & Africa Migraine Market Size by Type (2018-2023)
8.3 Middle East & Africa Migraine Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Migraine Market Forecast
10.1 Global Migraine Forecast by Regions (2024-2029)
10.1.1 Global Migraine Forecast by Regions (2024-2029)
10.1.2 Americas Migraine Forecast
10.1.3 APAC Migraine Forecast
10.1.4 Europe Migraine Forecast
10.1.5 Middle East & Africa Migraine Forecast
10.2 Americas Migraine Forecast by Country (2024-2029)
10.2.1 United States Migraine Market Forecast
10.2.2 Canada Migraine Market Forecast
10.2.3 Mexico Migraine Market Forecast
10.2.4 Brazil Migraine Market Forecast
10.3 APAC Migraine Forecast by Region (2024-2029)
10.3.1 China Migraine Market Forecast
10.3.2 Japan Migraine Market Forecast
10.3.3 Korea Migraine Market Forecast
10.3.4 Southeast Asia Migraine Market Forecast
10.3.5 India Migraine Market Forecast
10.3.6 Australia Migraine Market Forecast
10.4 Europe Migraine Forecast by Country (2024-2029)
10.4.1 Germany Migraine Market Forecast
10.4.2 France Migraine Market Forecast
10.4.3 UK Migraine Market Forecast
10.4.4 Italy Migraine Market Forecast
10.4.5 Russia Migraine Market Forecast
10.5 Middle East & Africa Migraine Forecast by Region (2024-2029)
10.5.1 Egypt Migraine Market Forecast
10.5.2 South Africa Migraine Market Forecast
10.5.3 Israel Migraine Market Forecast
10.5.4 Turkey Migraine Market Forecast
10.5.5 GCC Countries Migraine Market Forecast
10.6 Global Migraine Forecast by Type (2024-2029)
10.7 Global Migraine Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Pfizer
11.1.1 Pfizer Company Information
11.1.2 Pfizer Migraine Product Offered
11.1.3 Pfizer Migraine Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Pfizer Main Business Overview
11.1.5 Pfizer Latest Developments
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Information
11.2.2 GlaxoSmithKline Migraine Product Offered
11.2.3 GlaxoSmithKline Migraine Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 GlaxoSmithKline Main Business Overview
11.2.5 GlaxoSmithKline Latest Developments
11.3 Allergan
11.3.1 Allergan Company Information
11.3.2 Allergan Migraine Product Offered
11.3.3 Allergan Migraine Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Allergan Main Business Overview
11.3.5 Allergan Latest Developments
11.4 Amgen
11.4.1 Amgen Company Information
11.4.2 Amgen Migraine Product Offered
11.4.3 Amgen Migraine Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Amgen Main Business Overview
11.4.5 Amgen Latest Developments
11.5 Eli Lilly
11.5.1 Eli Lilly Company Information
11.5.2 Eli Lilly Migraine Product Offered
11.5.3 Eli Lilly Migraine Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Eli Lilly Main Business Overview
11.5.5 Eli Lilly Latest Developments
11.6 Teva Pharma
11.6.1 Teva Pharma Company Information
11.6.2 Teva Pharma Migraine Product Offered
11.6.3 Teva Pharma Migraine Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Teva Pharma Main Business Overview
11.6.5 Teva Pharma Latest Developments
11.7 Biohaven Pharma
11.7.1 Biohaven Pharma Company Information
11.7.2 Biohaven Pharma Migraine Product Offered
11.7.3 Biohaven Pharma Migraine Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Biohaven Pharma Main Business Overview
11.7.5 Biohaven Pharma Latest Developments
11.8 Abbott Laboratories
11.8.1 Abbott Laboratories Company Information
11.8.2 Abbott Laboratories Migraine Product Offered
11.8.3 Abbott Laboratories Migraine Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Abbott Laboratories Main Business Overview
11.8.5 Abbott Laboratories Latest Developments
11.9 Johnson & Johnson
11.9.1 Johnson & Johnson Company Information
11.9.2 Johnson & Johnson Migraine Product Offered
11.9.3 Johnson & Johnson Migraine Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Johnson & Johnson Main Business Overview
11.9.5 Johnson & Johnson Latest Developments
11.10 Valeant Pharma
11.10.1 Valeant Pharma Company Information
11.10.2 Valeant Pharma Migraine Product Offered
11.10.3 Valeant Pharma Migraine Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Valeant Pharma Main Business Overview
11.10.5 Valeant Pharma Latest Developments
12 Research Findings and Conclusion